Synergistic bactericidal interaction of josamycin with human neutrophils in vitro.
Josamycin and erythromycin have been compared for their in-vitro interaction with bactericidal killing by human neutrophils. The mechanism of this interaction was studied in two ways. First, the target organisms (Staphylococcus aureus and Pseudomonas aeruginosa) were incubated for 60 min with josamycin, erythromycin or control buffer prior to use in a human polymorphonuclear neutrophil (PMN) killing assay. Second the macrolides were added directly to acellular killing systems mimicking those acting inside the phagolysosome; oxygen-independent systems were obtained from a crude granule extract of PMN and oxygen-dependent systems consisted either of a mixture of xanthine plus xanthine oxidase or of a solution of H2O2. Whereas josamycin-pretreated P. aeruginosa were twice as sensitive to killing by PMN than were control cells, this was not the case for S. aureus. Both oxidant generating systems were more effective in destroying S. aureus in the presence of josamycin (3 and 30 mg/l). Erythromycin showed a similar synergy but only with the xanthine plus xanthine oxidase system. This synergy was observed with neither of the O2-independent systems for S. aureus, nor with any acellular system for P. aeruginosa. These data suggest that at least two kinds of mechanism may explain the bactericidal synergy observed between macrolides and PMN. The first (for macrolide-resistant species such as P. aeruginosa) could be due to alterations in the bacteria by the antibiotics, while the second (for macrolide-sensitive species such as S. aureus) could be based upon an as yet unexplained transformation of the molecules by reactive oxygen species into more "toxic" forms. These differences between josamycin and erythromycin could arise from differences in their chemical structure.
Labro
M T
MT
INSERM U. 294, CHU Xavier Bichat, Paris, France.
el Benna
J
J
D001770:Blood Bactericidal Activity / Q000187:drug effects*; D004121:Dimethyl Sulfoxide / Q000494:pharmacology; D004917:Erythromycin / Q000494:pharmacology; D005609:Free Radicals; D006801:Humans; D066298:In Vitro Techniques; D015570:Josamycin / Q000378:metabolism / Q000494:pharmacology*; D009504:Neutrophils / Q000276:immunology*; D011550:Pseudomonas aeruginosa / Q000187:drug effects; D013211:Staphylococcus aureus / Q000187:drug effects
D005609:Free Radicals; D004917:Erythromycin; D015570:Josamycin; D004121:Dimethyl Sulfoxide